262 related articles for article (PubMed ID: 32757514)
1. [Hormone treatment of transgender people: Long-term health effects and safety].
de Blok CJM; Wiepjes CM; Nota NM; den Heijer M
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32757514
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men.
van Heesewijk JO; Dreijerink KMA; Wiepjes CM; Kok AAL; van Schoor NM; Huisman M; den Heijer M; Kreukels BPC
J Sex Med; 2021 Aug; 18(8):1434-1443. PubMed ID: 34247950
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.
de Blok CJM; Wiepjes CM; Nota NM; van Engelen K; Adank MA; Dreijerink KMA; Barbé E; Konings IRHM; den Heijer M
BMJ; 2019 May; 365():l1652. PubMed ID: 31088823
[TBL] [Abstract][Full Text] [Related]
4. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.
Getahun D; Nash R; Flanders WD; Baird TC; Becerra-Culqui TA; Cromwell L; Hunkeler E; Lash TL; Millman A; Quinn VP; Robinson B; Roblin D; Silverberg MJ; Safer J; Slovis J; Tangpricha V; Goodman M
Ann Intern Med; 2018 Aug; 169(4):205-213. PubMed ID: 29987313
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease in transgender people: a systematic review and meta-analysis.
van Zijverden LM; Wiepjes CM; van Diemen JJK; Thijs A; den Heijer M
Eur J Endocrinol; 2024 Feb; 190(2):S13-S24. PubMed ID: 38302717
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular implications of gender-affirming hormone treatment in the transgender population.
Dutra E; Lee J; Torbati T; Garcia M; Merz CNB; Shufelt C
Maturitas; 2019 Nov; 129():45-49. PubMed ID: 31547912
[TBL] [Abstract][Full Text] [Related]
7. Sperm quality in transgender women before or after gender affirming hormone therapy-A prospective cohort study.
Rodriguez-Wallberg KA; Häljestig J; Arver S; Johansson ALV; Lundberg FE
Andrology; 2021 Nov; 9(6):1773-1780. PubMed ID: 33683832
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis and Bone Health in Transgender Persons.
Stevenson MO; Tangpricha V
Endocrinol Metab Clin North Am; 2019 Jun; 48(2):421-427. PubMed ID: 31027549
[TBL] [Abstract][Full Text] [Related]
9. Gender-Affirming Hormone Therapy Modifies the CpG Methylation Pattern of the ESR1 Gene Promoter After Six Months of Treatment in Transmen.
Fernández R; Ramírez K; Gómez-Gil E; Cortés-Cortés J; Mora M; Aranda G; Zayas ED; Esteva I; Almaraz MC; Guillamon A; Pásaro E
J Sex Med; 2020 Sep; 17(9):1795-1806. PubMed ID: 32636163
[TBL] [Abstract][Full Text] [Related]
10. Endocrinology of Transgender Medicine.
T'Sjoen G; Arcelus J; Gooren L; Klink DT; Tangpricha V
Endocr Rev; 2019 Feb; 40(1):97-117. PubMed ID: 30307546
[TBL] [Abstract][Full Text] [Related]
11. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
Glintborg D; T'Sjoen G; Ravn P; Andersen MS
Eur J Endocrinol; 2021 Jun; 185(2):R49-R63. PubMed ID: 34081614
[TBL] [Abstract][Full Text] [Related]
12. Transmasculine Hormone Therapy.
Defreyne J; T'Sjoen G
Endocrinol Metab Clin North Am; 2019 Jun; 48(2):357-375. PubMed ID: 31027545
[TBL] [Abstract][Full Text] [Related]
13. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men.
Pirtea P; Ayoubi JM; Desmedt S; T'Sjoen G
Fertil Steril; 2021 Oct; 116(4):936-942. PubMed ID: 34481638
[TBL] [Abstract][Full Text] [Related]
14. Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: a quantitative systematic review.
Rowniak S; Bolt L; Sharifi C
JBI Database System Rev Implement Rep; 2019 Sep; 17(9):1826-1854. PubMed ID: 31021971
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study.
Aldridge Z; Patel S; Guo B; Nixon E; Pierre Bouman W; Witcomb GL; Arcelus J
Andrology; 2021 Nov; 9(6):1808-1816. PubMed ID: 32777129
[TBL] [Abstract][Full Text] [Related]
16. Endocrinological and ovarian histological investigations in assigned female at birth transgender people undergoing testosterone therapy.
Borrás A; Manau MD; Fabregues F; Casals G; Saco A; Halperin I; Mora M; Goday A; Barral Y; Carmona F
Reprod Biomed Online; 2021 Aug; 43(2):289-297. PubMed ID: 34244072
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population.
Alzahrani T; Nguyen T; Ryan A; Dwairy A; McCaffrey J; Yunus R; Forgione J; Krepp J; Nagy C; Mazhari R; Reiner J
Circ Cardiovasc Qual Outcomes; 2019 Apr; 12(4):e005597. PubMed ID: 30950651
[TBL] [Abstract][Full Text] [Related]
18. Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals.
Wiik A; Lundberg TR; Rullman E; Andersson DP; Holmberg M; Mandić M; Brismar TB; Dahlqvist Leinhard O; Chanpen S; Flanagan JN; Arver S; Gustafsson T
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31794605
[TBL] [Abstract][Full Text] [Related]
19. Cancer Risk in Transgender People.
de Blok CJM; Dreijerink KMA; den Heijer M
Endocrinol Metab Clin North Am; 2019 Jun; 48(2):441-452. PubMed ID: 31027551
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment.
Masumori N; Nakatsuka M
Circ Rep; 2023 Apr; 5(4):105-113. PubMed ID: 37025940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
